The US FDA is set to introduce a faster approval process for personalized gene editing therapies, aiming to accelerate investment and development of treatments for rare diseases, highlighted by the ...
Nantucket High School and the Egan Maritime Institute will bring island students to the Marine Biological Laboratory in Woods ...
Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
According to MarketsandMarkets™, The agriculture biotechnology market is projected to grow from USD 92.19 billion in 2025 to USD 144.25 ...
A research team has successfully engineered a japonica rice variety using CRISPR/Cas9 to simultaneously optimize plant ...
A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...
A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...
Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.
With the demand for human donor organs desperately outstripping supply, scientists are working to see if genetically edited ...
Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback